I recently read about a company called VidaMed which has a revolutionary medical product called TUNA. TUNA is used to treat
BPH, also known as an enlarged prostate. TUNA is minimally
invasive, cost-effective, and is more effective than current
surgical procedures or drug therapies.
I did some research on VidaMed and Hambrecht and Quist and
Volpe Welty both have strong buy recommendations on the company.
According to H&Q analyst Robert Faulkner, FDA approval for
TUNA (Trans Urethral Needle Ablation) will occur with high
probability before the end of September. The FDA has reviewed TUNA extensively and would like to approve the product before VIDA's fiscal year ends on September 30. TUNA is a high-profile product and when the FDA approves it (very likely) they (the FDA) will issue its own press release-the FDA rarely issues its own press release. Finally, revenues are expected to mushroom from $5 M now to about $114 M.
This company is well positioned in a large market-each year
14 million men in the U.S. alone are treated for BPH at a cost of about $5BILLION. In a cost-conscious health care environment, this is a product that will gain wide acceptance and market share. If anyone has any information about VIDA it would be greatly appreciated if you posted it here. (VIDA is up to about 13.5 right now-it was at 12.00
two days ago) Is this company below Wall Street's radar screen?
|
